Inmune Bio Inc (INMB)

$INMB. INmune Bio (INMB) price target increased by 33.33% to 7.14 $SPY $QQQ $GSK https://www.msn.com/en-us/money/topstocks/inmune-bio-inmb-price-target-increased-by-33-33-to-7-14/ar-AA1ZyC5e

$INMB nobody cares anymore until all of a sudden they do. Lost the popularity contest and are in the dog house. A respectable partner on any of their programs will add to their legitimacy. I think the bottom is finally in.

$LAES $INMB $SPY if only LAES and INMB would go to the moon. A man can dream. Reddit junkies and traders alike, I wish you well.

$ARTL $INMB $PYXS $RADX

Jones Research reiterates a Buy on Radiopharm (RADX), . The key driver is RAD101, which has now shown consistently strong detection rates (~90% across interim analyses in brain metastases post-SRS), reinforcing earlier validation data and confirming a clear clinical gap where MRI struggles due to radiation necrosis. With final Phase 2b data approaching and trending toward high sensitivity (potentially ~26–27/30 patients), RAD101 is increasingly de-risked and positioned as a first-in-class asset in a niche with no direct competition, supporting meaningful commercial potential (~$500M+ peak sales). Combined with partnership interest, upcoming readouts across the pipeline (including RAD204), and optionality for non-dilutive deals, the current valuation appears disconnected from the probability-weighted upside—making the stock attractive ahead of a major data catalyst. $ARTL $INMB $PYXS $RADX

Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a B2i Digital Featured Company, will present its clinical and commercial progress at the Emerging Growth Conference 91 on April 2, 2026, at 10:15 AM ET. The presentation will be conducted via interactive webcast, and investors, advisors, and analysts are invited to attend. See Jupiter Neurosciences’ B2i Digital Featured Companies profile: https://b2idigital.com/jupiter-neurosciences-1 The Emerging Growth Conference provides public companies an efficient platform to communicate new developments to the investment community, with an audience that includes potentially tens of thousands of individual and institutional investors as well as advisors and analysts. The company is expected to highlight its clinical and commercial progress, including the Phase IIa clinical program in Parkinson’s disease, the broader CNS and rare disease pipeline, and the Nugevia™ consumer longevity product line, all powered by the company’s proprietary JOTROL™ platform. Register for the live webcast: https://goto.webcasts.com/starthere.jsp?ei=1748971&tp_key=add80b0ab6&sti=juns An archived webcast will be available after the event on EmergingGrowth.com and the Emerging Growth YouTube Channel at https://www.YouTube.com/EmergingGrowthConference. Read the full press release: https://jupiterneurosciences.com/press-releases/?i=163719 Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marsh Hayward, Ph.D., Co-Founder and CSO. To learn more about the company, visit www.jupiterneurosciences.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $INMB, $ANVS, $AVXL, $ATHA, $XBI

$INMB Market is pumping and this trash is red.. Great job CEO..

$INMB added @ 1.10

$INMB Zero volume, heavy shorting, 45 million net loss. Its very hard to find anything bullish about this stock at the moment.

$INMB under $1 today Possibly by the opening bell